Product Name
CACNA1F, siRNA
Full Product Name
CACNA1F siRNA (Human)
Product Synonym Names
CACNAF1; Voltage-dependent L-type calcium channel subunit alpha-1F; Voltage-gated calcium channel subunit alpha Cav1.4
Product Gene Name
CACNA1F sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for O60840
Specificity
CACNA1F siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CACNA1F gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CACNA1F sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CACNA1F sirna
siRNA to inhibit CACNA1F expression using RNA interference
Applications Tested/Suitable for CACNA1F sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CACNA1F. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001243718.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001256789.2
[Other Products]
UniProt Primary Accession #
O60840
[Other Products]
UniProt Secondary Accession #
O43901; O95226; Q9UHB1; A6NI29; F5CIQ9[Other Products]
UniProt Related Accession #
O60840[Other Products]
Molecular Weight
214,033 Da
NCBI Official Full Name
voltage-dependent L-type calcium channel subunit alpha-1F isoform 2
NCBI Official Synonym Full Names
calcium channel, voltage-dependent, L type, alpha 1F subunit
NCBI Official Symbol
CACNA1F??[Similar Products]
NCBI Official Synonym Symbols
JM8; OA2; AIED; COD3; COD4; JMC8; CORDX; CSNB2; CORDX3; CSNB2A; CSNBX2; Cav1.4; Cav1.4alpha1
??[Similar Products]
NCBI Protein Information
voltage-dependent L-type calcium channel subunit alpha-1F
UniProt Protein Name
Voltage-dependent L-type calcium channel subunit alpha-1F
UniProt Synonym Protein Names
Voltage-gated calcium channel subunit alpha Cav1.4
Protein Family
Voltage-dependent L-type calcium channel
UniProt Gene Name
CACNA1F??[Similar Products]
UniProt Synonym Gene Names
CACNAF1??[Similar Products]
UniProt Entry Name
CAC1F_HUMAN
NCBI Summary for CACNA1F
This gene encodes a multipass transmembrane protein that functions as an alpha-1 subunit of the voltage-dependent calcium channel, which mediates the influx of calcium ions into the cell. The encoded protein forms a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. Mutations in this gene can cause X-linked eye disorders, including congenital stationary night blindness type 2A, cone-rod dystropy, and Aland Island eye disease. Alternatively spliced transcript variants encoding multiple isoforms have been observed. [provided by RefSeq, Aug 2013]
UniProt Comments for CACNA1F
CACNA1F: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin- GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Defects in CACNA1F are the cause of congenital stationary night blindness type 2A (CSNB2A). Congenital stationary night blindness is a non-progressive retinal disorder characterized by impaired night vision. Defects in CACNA1F are the cause of cone-rod dystrophy X- linked type 3 (CORDX3). CORDs are inherited retinal dystrophies belonging to the group of pigmentary retinopathies. CORDs are characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa. Defects in CACNA1F are the cause of Aaland island eye disease (AIED); also known as Forsius-Eriksson type ocular albinism. On the Aaland island in the Baltic Sea, AIED is an X-linked recessive retinal disease characterized by a combination of fundus hypopigmentation, decreased visual acuity due to foveal hypoplasia, nystagmus, astigmatism, protan color vision defect, myopia, and defective dark adaptation. Except for progression of axial myopia, the disease can be considered to be a stationary condition. Electroretinography reveals abnormalities in both photopic and scotopic functions. Belongs to the calcium channel alpha-1 subunit (TC 1.A.1.11) family. CACNA1F subfamily. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral; Membrane protein, multi-pass
Chromosomal Location of Human Ortholog: Xp11.23
Cellular Component: photoreceptor outer segment; integral to membrane; voltage-gated calcium channel complex; perikaryon
Molecular Function: voltage-gated calcium channel activity; metal ion binding; high voltage-gated calcium channel activity
Biological Process: cellular calcium ion homeostasis; visual perception; axonogenesis; retina development in camera-type eye; regulation of T cell receptor signaling pathway; dendrite morphogenesis; detection of light stimulus involved in visual perception; T cell homeostasis
Disease: Night Blindness, Congenital Stationary, Type 2a; Cone-rod Dystrophy, X-linked, 3; Aland Island Eye Disease
Research Articles on CACNA1F
1. analysis of Cav1.4 complexes alpha11.4, beta2, and alpha2delta4 in HEK293T cells and in mouse retina
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
